These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29378718)

  • 41. Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Sotgiu G; D'Ambrosio L; Centis R; Tiberi S; Esposito S; Dore S; Spanevello A; Migliori GB
    Int J Mol Sci; 2016 Mar; 17(3):373. PubMed ID: 26985890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB.
    Kliiman K; Altraja A
    Eur Respir J; 2009 May; 33(5):1085-94. PubMed ID: 19164345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.
    Pietersen E; Ignatius E; Streicher EM; Mastrapa B; Padanilam X; Pooran A; Badri M; Lesosky M; van Helden P; Sirgel FA; Warren R; Dheda K
    Lancet; 2014 Apr; 383(9924):1230-9. PubMed ID: 24439237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study.
    Keshavjee S; Gelmanova IY; Farmer PE; Mishustin SP; Strelis AK; Andreev YG; Pasechnikov AD; Atwood S; Mukherjee JS; Rich ML; Furin JJ; Nardell EA; Kim JY; Shin SS
    Lancet; 2008 Oct; 372(9647):1403-9. PubMed ID: 18723218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
    Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J;
    Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Laboratory-Based Surveillance of Extensively Drug-Resistant Tuberculosis in Eastern China.
    Huang Y; Wu Q; Xu S; Zhong J; Chen S; Xu J; Zhu L; He H; Wang X
    Microb Drug Resist; 2017 Mar; 23(2):236-240. PubMed ID: 27754791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence].
    Yoo JW; Lyu J; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2013 Sep; 17(9):1243-4. PubMed ID: 23928173
    [No Abstract]   [Full Text] [Related]  

  • 52. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Dalcolmo M; Gayoso R; Sotgiu G; D'Ambrosio L; Rocha JL; Borga L; Fandinho F; Braga JU; Galesi VM; Barreira D; Sanchez DA; Dockhorn F; Centis R; Caminero JA; Migliori GB
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
    Bastos ML; Lan Z; Menzies D
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan.
    Lai CC; Tan CK; Huang YT; Chou CH; Hung CC; Yang PC; Luh KT; Hsueh PR
    Clin Infect Dis; 2008 Oct; 47(7):e57-63. PubMed ID: 18715157
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Abdo Arbex M; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Auchynka V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2016 Jun; 47(6):1758-66. PubMed ID: 27076583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.
    Agyeman AA; Ofori-Asenso R
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):41. PubMed ID: 27334498
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
    Misra N; Padayatchi N; Naidoo P
    S Afr Med J; 2019 Dec; 110(1):32-37. PubMed ID: 31865940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multidrug- and extensively drug-resistant tuberculosis, Germany.
    Eker B; Ortmann J; Migliori GB; Sotgiu G; Muetterlein R; Centis R; Hoffmann H; Kirsten D; Schaberg T; Ruesch-Gerdes S; Lange C;
    Emerg Infect Dis; 2008 Nov; 14(11):1700-6. PubMed ID: 18976552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend.
    Rajasekaran S; Chandrasekar C; Mahilmaran A; Kanakaraj K; Karthikeyan DS; Suriakumar J
    J Indian Med Assoc; 2009 May; 107(5):281-2, 284-6. PubMed ID: 19886382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine.
    Abbate E; Vescovo M; Natiello M; Cufré M; García A; Gonzalez Montaner P; Ambroggi M; Ritacco V; van Soolingen D
    J Antimicrob Chemother; 2012 Feb; 67(2):473-7. PubMed ID: 22134348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.